SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation

Experimental Neurology

Volumn 254, Issue , 2014, Pages 180-189

  Robson, Matthew J ^a,b   Turner, Ryan C ^c   Naser, Zachary J ^c   McCurdy, Christopher R ^d,e   O'Callaghan, James P ^f   Huber, Jason D ^a,c   Matsumoto, Rae R ^a,c  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d UNIVERSITY OF MISSISSIPPI   (United States)

^e UNIVERSITY OF MISSISSIPPI   (United States)

^f NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Astrocyte; Glia; Methamphetamine neurotoxicity; Neuroinflammation; Sigma receptor

Indexed keywords

ASTROCYTE; GLIA; METHAMPHETAMINE NEUROTOXICITY; NEUROINFLAMMATION; SIGMA RECEPTOR;

ANIMALS; ASTROCYTES; BENZOXAZOLES; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; CYTOKINE RECEPTOR GP130; DOPAMINERGIC NEURONS; DRUG INTERACTIONS; FEVER; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; MALE; METHAMPHETAMINE; MICE; ONCOSTATIN M RECEPTOR BETA SUBUNIT; PHOSPHORYLATION; PIPERAZINES; RECEPTORS, SIGMA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84894079730     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.01.020     Document Type: Article

References (77)

1. Ajmo C.T., Vernon D.O., Collier L., Pennypacker K.R., Cuevas J. Sigma receptor activation reduces infarct size at 24h after permanent middle cerebral artery occlusion in rats. Curr. Neurovasc. Res. 2006, 3:89-98.
2. Anderson K.J., Fugaccia I., Scheff S.W. Fluoro-Jade B stains quiescent and reactive astrocytes in the rodent spinal cord. J. Neurotrauma 2003, 20:1223-1231.
3. Baker B.J., Qin H., Benveniste E.N. Molecular basis of oncostatin M-induced SOCS-3 expression in astrocytes. Glia 2008, 56:1250-1262.
4. Bolte S., Cordelieres F.P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 2006, 224:213-232.
5. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker W., Holson R.R. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 1994, 268:1571-1580.
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
7. Cadet J.L., Krasnova I.N. Molecular bases of methamphetamine-induced neurodegeneration. Int. Rev. Neurobiol. 2009, 88:101-119.
8. Cadet J.L., McCoy M.T., Ladenheim B. Distinct gene expression signatures in the striata of wild-type and heterozygous c-fos knockout mice following methamphetamine administration: evidence from cDNA array analyses. Synapse 2002, 44:211-226.
9. Callaghan R.C., Cunningham J.K., Sajeev G., Kish S.J. Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov. Disord. 2010, 25:2333-2339.
10. Callaghan R.C., Cunningham J.K., Sykes J., Kish S.J. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend. 2012, 120:35-40.
11. Cantarella G., Bucolo C., Di Benedetto G., Pezzino S., Lempereur L., Calvagna R., Clementi S., Pavone P., Fiore L., Bernardini R. Protective effects of the sigma agonist Pre-084 in the rat retina. Br. J. Ophthalmol. 2007, 91:1382-1384.
12. Chen S.H., Benveniste E.N. Oncostatin M: a pleiotropic cytokine in the central nervous system. Cytokine Growth Factor Rev. 2004, 15:379-391.
13. Chen S.H., Gillespie G.Y., Benveniste E.N. Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases. Glia 2006, 53:191-200.
14. Chen J.C., Chen P.C., Chiang Y.C. Molecular mechanisms of psychostimulant addiction. Chang Gung Med. J. 2009, 32:148-154.
15. Cooper Z.D., Jones J.D., Comer S.D. Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances. Expert Opin. Investig. Drugs 2012, 21:169-178.
16. Damjanac M., Rioux Bilan A., Barrier L., Pontcharraud R., Anne C., Hugon J., Page G. Fluoro-Jade B staining as useful tool to identify activated microglia and astrocytes in a mouse transgenic model of Alzheimer's disease. Brain Res. 2007, 1128:40-49.
17. Deng X., Wang Y., Chou J., Cadet J.L. Methamphetamine causes widespread apoptosis in the mouse brain: evidence from using an improved TUNEL histochemical method. Brain Res. Mol. Brain Res. 2001, 93:64-69.
18. Eisch A.J., Schmued L.C., Marshall J.F. Characterizing cortical neuron injury with Fluoro-Jade labeling after a neurotoxic regimen of methamphetamine. Synapse 1998, 30:329-333.
19. Fontanilla D., Johannessen M., Hajipour A.R., Cozzi N.V., Jackson M.B., Ruoho A.E. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009, 323:934-937.
20. Hebert M.A., O'Callaghan J.P. Protein phosphorylation cascades associated with methamphetamine-induced glial activation. Ann. N. Y. Acad. Sci. 2000, 914:238-262.
21. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
22. Hellewell S.B., Bowen W.D. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res. 1990, 527:244-253.
23. Jayanthi S., Deng X., Ladenheim B., McCoy M.T., Cluster A., Cai N.S., Cadet J.L. Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:868-873.
24. Kaushal N., Matsumoto R.R. Role of sigma receptors in methamphetamine-induced neurotoxicity. Curr. Neuropharmacol 2011, 9:54-57.
25. Kaushal N., Robson M.J., Vinnakota H., Narayanan S., Avery B.A., McCurdy C.R., Matsumoto R.R. Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS J. 2011, 13:336-346.
26. Kaushal N., Seminerio M.J., Shaikh J., Medina M.A., Mesangeau C., Wilson L.L., McCurdy C.R., Matsumoto R.R. CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice. Neuropharmacology 2011, 61:992-1000.
27. Kaushal N., Seminerio M.J., Robson M.J., McCurdy C.R., Matsumoto R.R. Pharmacological evaluation of SN79, a sigma (σ) receptor ligand, against methamphetamine-induced neurotoxicity in vivo. Eur. Neuropsychopharmacol. 2013, 23:960-971.
28. Kelly K.A., Miller D.B., Bowyer J.F., O'Callaghan J.P. Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamine. J. Neurochem. 2012, 122:995-1009.
29. Klouz A., Tillement J.P., Boussard M.F., Wierzbicki M., Berezowski V., Cecchelli R., Labidalle S., Onteniente B., Morin D. [3H]BHDP as a novel and selective ligand for sigma1 receptors in liver mitochondria and brain synaptosomes of the rat. FEBS Lett. 2003, 553:157-162.
30. Kuhn D.M., Francescutti-Verbeem D.M., Thomas D.M. Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann. N. Y. Acad. Sci. 2006, 1074:31-41.
31. Lau J.W., Senok S., Stadlin A. Methamphetamine-induced oxidative stress in cultured mouse astrocytes. Ann. N. Y. Acad. Sci. 2000, 914:146-156.
32. Matsumoto R.R., Shaikh J., Wilson L.L., Vedam S., Coop A. Attenuation of methamphetamine-induced effects through the antagonism of sigma (σ) receptors: evidence from in vivo and in vitro studies. Eur. Neuropsychopharmacol. 2008, 18:871-881.
33. Miguel-Hidalgo J.J. The role of glial cells in drug abuse. Curr. Drug Abuse Rev. 2009, 2:72-82.
34. Nakashima K., Wiese S., Yanagisawa M., Arakawa H., Kimura N., Hisatsune T., Yoshida K., Kishimoto T., Sendtner M., Taga T. Developmental requirement of gp130 signaling in neuronal survival and astrocyte differentiation. J. Neurosci. 1999, 19:5429-5434.
35. Narita M., Miyatake M., Shibasaki M., Tsuda M., Koizumi S., Yajima Y., Inoue K., Suzuki T. Long-lasting change in brain dynamics induced by methamphetamine: enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization. J. Neurochem. 2005, 93:1383-1392.
36. Narita M., Miyatake M., Shibasaki M., Shindo K., Nakamura A., Kuzumaki N., Nagumo Y., Suzuki T. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 2006, 31:2476-2488.
37. Narita M., Suzuki M., Kuzumaki N., Miyatake M., Suzuki T. Implication of activated astrocytes in the development of drug dependence: differences between methamphetamine and morphine. Ann. N. Y. Acad. Sci. 2008, 1141:96-104.
38. Nedergaard M., Verkhratsky A. Artifact versus reality-how astrocytes contribute to synaptic events. Glia 2012, 60:1013-1023.
39. Nguyen E.C., McCracken K.A., Liu Y., Pouw B., Matsumoto R.R. Involvement of sigma (σ) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology 2005, 49:638-645.
40. Nishimura T., Ishima T., Iyo M., Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One 2008, 3:e2558.
41. O'Callaghan J.P., Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 1994, 270:741-751.
42. O'Callaghan J.P., Sriram K. Focused microwave irradiation of the brain preserves in vivo protein phosphorylation: comparison with other methods of sacrifice and analysis of multiple phosphoproteins. J. Neurosci. Methods 2004, 135:159-168.
43. Oliva A.A., Kang Y., Sanchez-Molano J., Furones C., Atkins C.M. STAT3 signaling after traumatic brain injury. J. Neurochem. 2012, 120:710-720.
44. Prezzavento O., Campisi A., Ronsisvalle S., Li Volti G., Marrazzo A., Bramanti V., Cannavo G., Vanella L., Cagnotto A., Mennini T., et al. Novel sigma receptor ligands: synthesis and biological profile. J. Med. Chem. 2007, 50:951-961.
45. Pu C., Fisher J.E., Cappon G.D., Vorhees C.V. The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum. Brain Res. 1994, 649:217-224.
46. Raivich G., Bohatschek M., Kloss C.U., Werner A., Jones L.L., Kreutzberg G.W. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res. Brain Res. Rev. 1999, 30:77-105.
47. Reichel C.M., Ramsey L.A., Schwendt M., McGinty J.F., See R.E. Methamphetamine-induced changes in the object recognition memory circuit. Neuropharmacology 2012, 62:1119-1126.
48. Robson M.J., Turner R.C., Naser Z.J., McCurdy C.R., Huber J.D., Matsumoto R.R. SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation. Exp. Neurol. 2013, 247:134-142.
49. Rolan P., Hutchinson M., Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin. Pharmacother. 2009, 10:2897-2904.
50. Romanelli F., Smith K.M. Clinical effects and management of methamphetamine abuse. Pharmacotherapy 2006, 26:1148-1156.
51. Ruscher K., Shamloo M., Rickhag M., Ladunga I., Soriano L., Gisselsson L., Toresson H., Ruslim-Litrus L., Oksenberg D., Urfer R., et al. The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain 2011, 134:732-746.
52. Schmitz C., Hof P.R. Design-based stereology in neuroscience. Neuroscience 2005, 130:813-831.
53. Schmued L.C., Hopkins K.J. Fluoro-Jade: novel fluorochromes for detecting toxicant-induced neuronal degeneration. Toxicol. Pathol. 2000, 28:91-99.
54. Schwendt M., Rocha A., See R.E., Pacchioni A.M., McGinty J.F., Kalivas P.W. Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion. J. Pharmacol. Exp. Ther. 2009, 331:555-562.
55. Seminerio M.J., Kaushal N., Shaikh J., Huber J.D., Coop A., Matsumoto R.R. Sigma (σ) receptor ligand, AC927 (N-phenethylpiperidine oxalate), attenuates methamphetamine-induced hyperthermia and serotonin damage in mice. Pharmacol. Biochem. Behav. 2011, 98:12-20.
56. Seminerio M.J., Hansen R., Kaushal N., Zhang H.T., McCurdy C.R., Matsumoto R.R. The evaluation of AZ66, an optimized sigma receptor antagonist, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice. Int. J. Neuropsychopharmacol. 2012, 1-12.
57. Seminerio M.J., Robson M.J., Abdelazeem A.H., Mesangeau C., Jamalapuram S., Avery B.A., McCurdy C.R., Matsumoto R.R. Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine. AAPS J. 2012, 14:43-51.
58. Smith D.W., Bailes J.E., Fisher J.A., Robles J., Turner R.C., Mills J.D. Internal jugular vein compression mitigates traumatic axonal injury in a rat model by reducing the intracranial slosh effect. Neurosurgery 2012, 70:740-746.
59. Son J.S., Kwon Y.B. Sigma-1 receptor antagonist BD1047 reduces allodynia and spinal ERK phosphorylation following chronic compression of dorsal root ganglion in rats. Korean J. Physiol. Pharmacol. 2010, 14:359-364.
60. Sriram K., Benkovic S.A., Hebert M.A., Miller D.B., O'Callaghan J.P. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo?. J. Biol. Chem. 2004, 279:19936-19947.
61. Sriram K., Miller D.B., O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 2006, 96:706-718.
62. Stadlin A., Lau J.W., Szeto Y.K. A selective regional response of cultured astrocytes to methamphetamine. Ann. N. Y. Acad. Sci. 1998, 844:108-121.
63. Tan F., Guio-Aguilar P.L., Downes C., Zhang M., O'Donovan L., Callaway J.K., Crack P.J. The sigma 1 receptor agonist 4-PPBP elicits ERK1/2 phosphorylation in primary neurons: a possible mechanism of neuroprotective action. Neuropharmacology 2010, 59:416-424.
64. Thomas D.M., Francescutti-Verbeem D.M., Liu X., Kuhn D.M. Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment-an oligonucleotide microarray approach. J. Neurochem. 2004, 88:380-393.
65. Todd G., Noyes C., Flavel S.C., Della Vedova C.B., Spyropoulos P., Chatterton B., Berg D., White J.M. Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PLoS One 2013, 8:e56438.
66. Tuerxun T., Numakawa T., Adachi N., Kumamaru E., Kitazawa H., Kudo M., Kunugi H. SA4503, a sigma-1 receptor agonist, prevents cultured cortical neurons from oxidative stress-induced cell death via suppression of MAPK pathway activation and glutamate receptor expression. Neurosci. Lett. 2010, 469:303-308.
67. Turner R.C., Naser Z.J., Bailes J.E., Smith D.W., Fisher J.A., Rosen C.L. Effect of slosh mitigation on histologic markers of traumatic brain injury: laboratory investigation. J. Neurosurg. 2012, 117:1110-1118.
68. Ujike H., Kanzaki A., Okumura K., Akiyama K., Otsuki S. Sigma antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sci. 1992, 50:PL129-PL134.
69. Ujike H., Kuroda S., Otsuki S. Sigma receptor antagonists block the development of sensitization to cocaine. Eur. J. Pharmacol. 1996, 296:123-128.
70. Ullian E.M., Christopherson K.S., Barres B.A. Role for glia in synaptogenesis. Glia 2004, 47:209-216.
71. Van Wagoner N.J., Benveniste E.N. Interleukin-6 expression and regulation in astrocytes. J. Neuroimmunol. 1999, 100:124-139.
72. Van Wagoner N.J., Choi C., Repovic P., Benveniste E.N. Oncostatin M regulation of interleukin-6 expression in astrocytes: biphasic regulation involving the mitogen-activated protein kinases ERK1/2 and p38. J. Neurochem. 2000, 75:563-575.
73. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M., Gatley S.J., Miller E., Hitzemann R., Ding Y.S., et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 2001, 21:9414-9418.
74. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 2001, 158:377-382.
75. Xu Y.T., Kaushal N., Shaikh J., Wilson L.L., Mesangeau C., McCurdy C.R., Matsumoto R.R. A novel substituted piperazine, CM156, attenuates the stimulant and toxic effects of cocaine in mice. J. Pharmacol. Exp. Ther. 2010, 333:491-500.
76. Zamanian J.L., Xu L., Foo L.C., Nouri N., Zhou L., Giffard R.G., Barres B.A. Genomic analysis of reactive astrogliosis. J. Neurosci. 2012, 32:6391-6410.
77. Zhong Z., Wen Z., Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.